| 1401 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Germany |
21 |
| 1402 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy |
Denmark |
65 |
| 1403 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Romania |
25 |
| 1404 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Italy |
27 |
| 1405 |
Apheresis |
Allogeneic
|
Polycythaemia Vera
|
Hematology
|
2025
|
Standard Therapy |
Germany |
61 |
| 1406 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Poland |
25 |
| 1407 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Poland |
51 |
| 1408 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy |
Germany |
70 |
| 1409 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Germany |
53 |
| 1410 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Lithuania |
61 |
| 1411 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Russian Federation |
49 |
| 1412 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Poland |
36 |
| 1413 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
France |
62 |
| 1414 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
USA |
54 |
| 1415 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy |
USA |
74 |
| 1416 |
Apheresis |
Allogeneic
|
NHL Non-Hodgkin Lymphoma
|
Hematology
|
2025
|
Standard Therapy |
Poland |
49 |
| 1417 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
USA |
62 |
| 1418 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2025
|
Standard Therapy |
USA |
74 |
| 1419 |
Apheresis |
Allogeneic
|
NHL Non-Hodgkin Lymphoma
|
Hematology
|
2025
|
Standard Therapy |
Argentine |
57 |
| 1420 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy |
Germany |
56 |
| 1421 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Belgium |
71 |
| 1422 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Spain |
59 |
| 1423 |
Apheresis |
Allogeneic
|
Other Myelofibrosis/Myelosclerosis
|
Hematology
|
2025
|
Standard Therapy |
USA |
65 |
| 1424 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Poland |
14 |
| 1425 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Denmark |
57 |
| 1426 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Germany |
68 |
| 1427 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Poland |
51 |
| 1428 |
Apheresis |
Allogeneic
|
Richter Transformation CDLBCC
|
Hematology
|
2025
|
Standard Therapy |
Germany |
68 |
| 1429 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia-MR
|
Hematology
|
2025
|
Standard Therapy |
Russian Federation |
16 |
| 1430 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Germany |
63 |
| 1431 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy |
USA |
66 |
| 1432 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Germany |
50 |
| 1433 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Poland |
38 |
| 1434 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
USA |
43 |
| 1435 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
USA |
74 |
| 1436 |
Apheresis |
Allogeneic
|
T-cell Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Poland |
51 |
| 1437 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
USA |
59 |
| 1438 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Poland |
66 |
| 1439 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Germany |
68 |
| 1440 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Poland |
33 |
| 1441 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Poland |
48 |
| 1442 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Netherlands |
66 |
| 1443 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy |
USA |
57 |
| 1444 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Belgium |
56 |
| 1445 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
USA |
55 |
| 1446 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Poland |
24 |
| 1447 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Italy |
61 |
| 1448 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
USA |
71 |
| 1449 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy |
Canada |
53 |
| 1450 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy |
Germany |
62 |
| 1451 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy |
Germany |
45 |
| 1452 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy |
Germany |
61 |
| 1453 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy |
Germany |
32 |
| 1454 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy |
Germany |
62 |
| 1455 |
Apheresis |
Autologous
|
Central Nervous System Lymphoma
|
Hematology
|
2025
|
Standard Therapy |
Germany |
75 |
| 1456 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2025
|
Standard Therapy |
Germany |
70 |
| 1457 |
Cord Tissue |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Romania |
6 |
| 1458 |
Cord Tissue |
Allogeneic – Related
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Romania |
6 |
| 1459 |
Cord Tissue |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Romania |
4 |
| 1460 |
Cord Tissue |
Allogeneic – Related
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Romania |
6 |
| 1461 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and Traumatic Cartilage
|
Orthopedics
|
2024
|
Experimental Therapy |
Poland |
50 |
| 1462 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and Traumatic Cartilage
|
Orthopedics
|
2024
|
Experimental Therapy |
Poland |
49 |
| 1463 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and Traumatic Cartilage
|
Orthopedics
|
2024
|
Experimental Therapy |
Poland |
58 |
| 1464 |
Cord Tissue |
Allogeneic – Unrelated
|
Graft Versus Host Disease
|
Hematology
|
2024
|
Experimental Therapy |
Poland |
7 |
| 1465 |
Cord Tissue |
Allogeneic – Unrelated
|
Graft Versus Host Disease
|
Hematology
|
2024
|
Experimental Therapy |
Poland |
15 |
| 1466 |
Cord Tissue |
Allogeneic – Unrelated
|
Ovarian Dysfunction
|
Gynecology
|
2024
|
Experimental Therapy |
Poland |
48 |
| 1467 |
Cord Tissue |
Allogeneic – Related
|
Severe Pulmonary Hypertension +Mitral Regurgitation
|
Cardiovascular/Pulmonary
|
2024
|
Experimental Therapy |
Romania |
2 |
| 1468 |
Cord Tissue |
Allogeneic – Unrelated
|
Amyotrophic lateral sclerosis
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
57 |
| 1469 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and traumatic cartilage damage
|
Orthopedics
|
2024
|
Experimental Therapy |
Poland |
68 |
| 1470 |
Cord Tissue |
Allogeneic – Related
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Romania |
17 |
| 1471 |
Cord Tissue |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Romania |
7 |
| 1472 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and traumatic cartilage damage
|
Orthopedics
|
2024
|
Experimental Therapy |
Poland |
61 |
| 1473 |
Cord Tissue |
Allogeneic – Unrelated
|
Degenerative and traumatic cartilage damage
|
Orthopedics
|
2024
|
Experimental Therapy |
Poland |
45 |
| 1474 |
Cord Tissue |
Allogeneic – Unrelated
|
Amyotrophic lateral sclerosis
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
56 |
| 1475 |
Cord Tissue |
Allogeneic – Unrelated
|
Graft-versus-host disease
|
Hematology
|
2024
|
Experimental Therapy |
Poland |
0 |
| 1476 |
Cord Tissue |
Allogeneic – Unrelated
|
Amyotrophic lateral sclerosis
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
39 |
| 1477 |
Cord Tissue |
Allogeneic – Unrelated
|
GvHD
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
9 |
| 1478 |
Cord Tissue |
Allogeneic – Unrelated
|
Cerebral palsy
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
5 |
| 1479 |
Cord Tissue |
Allogeneic – Unrelated
|
Cerebral palsy
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
13 |
| 1480 |
Cord Tissue |
Allogeneic – Unrelated
|
Leukodystrophy
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
1 |
| 1481 |
Cord Tissue |
Allogeneic – Unrelated
|
Cerebral Palsy
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
7 |
| 1482 |
Cord Tissue |
Allogeneic – Unrelated
|
Leukodystrophy
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
1 |
| 1483 |
Cord Tissue |
Allogeneic – Unrelated
|
Cerebellar-spinal ataxia
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
35 |
| 1484 |
Cord Tissue |
Allogeneic – Unrelated
|
Leukodystrophy
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
1 |
| 1485 |
Cord Tissue |
Allogeneic – Unrelated
|
Cerebral Palsy
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
4 |
| 1486 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Romania |
11 |
| 1487 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Romania |
10 |
| 1488 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Romania |
6 |
| 1489 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Romania |
4 |
| 1490 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Romania |
5 |
| 1491 |
Cord Blood |
Allogeneic
|
Cerebral Palsy
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
3 |
| 1492 |
Cord Blood |
Allogeneic
|
Cerebral Palsy
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
7 |
| 1493 |
Cord Blood |
Autologous
|
CP
|
Neurology
|
2024
|
Experimental Therapy |
Hungary |
4 |
| 1494 |
Cord Blood |
Autologous
|
Pervasive Developmental Disorder
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
3 |
| 1495 |
Cord Blood |
Autologous
|
Pervasive Developmental Disorder
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
5 |
| 1496 |
Cord Blood |
Autologous
|
Pervasive developmental disorder
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
4 |
| 1497 |
Cord Blood |
Allogeneic – Related
|
fanconi aplastic anemia
|
Hematology
|
2024
|
Standard Therapy |
Turkey |
12 |
| 1498 |
Cord Blood |
Autologous
|
Neuroblastoma
|
Neurology
|
2024
|
Standard Therapy |
Poland |
4 |
| 1499 |
Cord Blood |
Autologous
|
Pervasive developmental disorder
|
Neurology
|
2024
|
Experimental Therapy |
Poland |
9 |
| 1500 |
Cord Blood |
Autologous
|
Autism
|
Neurology
|
2024
|
Experimental Therapy |
Slovakia |
4 |
Albánia
Bosznia Herzegovina
Bulgária
Horvátország
Ciprus
Montenegró
Cseh Köztársaság
Dánia
Észtország
Spanyolország
Koszovó
Litvánia
Lettország
Luxemburg
Macedónia
Németország
Lengyelország
Portugália
Románia
Szerbia
Szlovákia
Szlovénia
Svájc
Svédország
Törökország
Magyarország
Egyesült Királyság
Olaszország
UAE
Hong-Kong
Kuvait
Libanon
Dél-Afrika
